Incannex Wins R&D Award for Sleep Apnea Drug in 2025 Clinical Trials Arena Excellence Awards

Event summary

  • Incannex Healthcare received the Research and Development Award in the Respiratory Disorders category for its obstructive sleep apnea (OSA) program IHL-42X.
  • The award was presented as part of the 2025 Clinical Trials Arena Excellence Awards, which evaluates over one billion datasets annually.
  • IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, targeting moderate-to-severe OSA patients who struggle with device-based therapies.
  • The Phase 2 clinical program for IHL-42X integrated polysomnography outcomes and patient-reported measures, showing favorable safety and tolerability.
  • Incannex's pipeline includes three clinical-stage programs: IHL-42X, IHL-675A for rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.

The big picture

Incannex's award highlights the growing interest in non-invasive, pharmacologic alternatives for OSA, a condition with significant unmet medical needs. The recognition underscores the strategic shift toward combination therapies targeting underlying biological pathways in chronic conditions. With a pipeline spanning respiratory, inflammatory, and mental health disorders, Incannex is positioning itself as a player in evidence-based innovation for underserved markets.

What we're watching

Clinical Progress
The pace at which IHL-42X advances through late-stage development and regulatory approvals will determine its market potential.
Competitive Positioning
Whether Incannex can differentiate IHL-42X in a market dominated by device-based therapies for OSA.
Pipeline Strategy
How Incannex balances its focus on combination therapies across multiple chronic conditions, including rheumatoid arthritis and anxiety disorder.